<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566863</url>
  </required_header>
  <id_info>
    <org_study_id>GUMed-Wu-003</org_study_id>
    <nct_id>NCT02566863</nct_id>
  </id_info>
  <brief_title>Haemodynamic Effect of Dexmedetomidine</brief_title>
  <official_title>Haemodynamic Effect of Dexmedetomidine in Relation to Autonomic System Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine, selective alfa2 receptors agonist produces sympatholysis. As a result heart
      rate decreases. With low doses blood pressure also decreases, with higher dosing - systematic
      vascular resistance increases. The indication for the drug is to produce sedation during
      surgical procedures and in ICU patients.

      The aim of a study is to verify, whether the haemodynamic effect (heart rate, blood pressure
      and heart rate variability during drug infusion) depend on pre-drug autonomic system
      activity. Autonomic system activity is assessed using heart rate variability (HRV)measurement
      before drug injection and during drug infusion. Heart rate and blood pressure measured before
      and during drug infusion will be analysed.

      HRV measurement analysis will be based on continuous Holter ECG recording, taken before drug
      injection and during its infusion. 5 minutes intervals will be analysed , using Frequency
      Domain Measures of HRV. Surgical procedure will start after measurement have been taken.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of haemodynamics and heart rate variability parameters</measure>
    <time_frame>up to 30 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Haemodynamic Effects of Dexmedetomidine</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine, 1 mcg/kg over 10 minutes, followed by a maintenance infusion, given to achieve sedation for eye surgery procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Dexdor</other_name>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients classified with American Society of Anesthesiologists Physical Status
             Classification System as 1 or 2 status

          -  planned eye surgery under sedation

        Exclusion Criteria:

          -  patient's refusal

          -  contraindications to dexmedetomidine

          -  diseases/drugs that influence on autonomic nervous system activity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena A Wujtewicz, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Medical University of Gda≈Ñsk</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magdalena A Wujtewicz, M.D</last_name>
    <email>magwuj@gumed.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Radoslaw Owczuk, M.D</last_name>
    <email>r.owczuk@gumed.edu.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena A Wujtewicz</last_name>
      <phone>+48583493357</phone>
      <email>magwuj@gumed.edu.pl</email>
    </contact>
    <contact_backup>
      <last_name>Radoslaw Owczuk</last_name>
      <phone>605408140</phone>
      <email>r.owczuk@gumed.edu.pl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Gdansk</investigator_affiliation>
    <investigator_full_name>Magdalena Wujtewicz</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>heart rate</keyword>
  <keyword>heart rate variability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

